About 28S rRNA (uridine-N(3))-methyltransferase
28S rRNA (uridine-N(3))-methyltransferase (SPOUT1) is a protein
from Homo sapiens identified by UniProt accession
Q5T280, 376 residues long.
MolForge cross-references it against 0 known binders and
32 disease associations.
Target properties
| Protein name | 28S rRNA (uridine-N(3))-methyltransferase |
| UniProt accession | Q5T280 |
| Gene | SPOUT1 |
| Organism | Homo sapiens |
| Length | 376 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (32)
Diseases linked to this target (Open Targets).
- Neurodevelopmental disorder · score 0.40
- serum metabolite measurement · score 0.19
- serum albumin measurement · score 0.18
- bilirubin measurement · score 0.17
- high density lipoprotein cholesterol measurement · score 0.15
- triglyceride measurement · score 0.13
- BMI-adjusted waist circumference · score 0.13
- blood metabolite measurement · score 0.11
- BMI-adjusted waist-hip ratio · score 0.10
- calcium measurement · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q5T280-F1 | alphafold | PREDICTED | 88.40 | — |
Amino-acid sequence (376 residues)
MAERGRKRPC GPGEHGQRIE WRKWKQQKKE EKKKWKDLKL MKKLERQRAQ EEQAKRLEEE EAAAEKEDRG RPYTLSVALP GSILDNAQSP ELRTYLAGQI ARACAIFCVD EIVVFDEEGQ DAKTVEGEFT GVGKKGQACV QLARILQYLE CPQYLRKAFF PKHQDLQFAG LLNPLDSPHH MRQDEESEFR EGIVVDRPTR PGHGSFVNCG MKKEVKIDKN LEPGLRVTVR LNQQQHPDCK TYHGKVVSSQ DPRTKAGLYW GYTVRLASCL SAVFAEAPFQ DGYDLTIGTS ERGSDVASAQ LPNFRHALVV FGGLQGLEAG ADADPNLEVA EPSVLFDLYV NTCPGQGSRT IRTEEAILIS LAALQPGLIQ AGARHT
Explore 28S rRNA (uridine-N(3))-methyltransferase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets